Media

페이지 정보

본문

GemVax Presents Poster on Topline Results of PSP Phase 2a Trial at 

International Conference

Attends 7th TIC-PDMD… “95% Delay in Disease Progression in PSP-RS Patients

GemVax & KAEL Co., Ltd. (hereinafter “GemVax,” KOSDAQ: 082270) announced the topline results of its Phase 2a clinical trial for progressive supranuclear palsy (PSP) through a poster presentation at an international academic conference.

According to GemVax, the company participated in the 7th Taiwan International Congress of Parkinson’s Disease and Movement Disorders (7th TIC-PDMD) held in Taipei, Taiwan, from February 22 to 24, where it presented the phase 2a clinical data on its PSP treatment candidate, GV1001.

TIC-PDMD, hosted biennially by the Taiwan Movement Disorder Society (TMDS), serves as a platform for sharing innovative research findings and novel therapeutic approaches in neurodegenerative diseases, particularly Parkinson’s disease and movement disorders.

Through the poster presentation, GemVax reported that the Phase 2a trial results demonstrated that the group receiving GV1001 (0.56 mg) experienced a 48% delay in disease progression compared to the placebo group. Moreover, when analyzing only PSP-Richardson Syndrome (PSP-RS) patients, who account for approximately 75% of PSP cases, the disease progression delay 

reached 95%.

These findings were first presented at Neuro2024, held in Toronto, Canada, last October. At the time, global experts highly praised the observed trend of GV1001 compared to the placebo group, as well as the drug’s safety profile..

Professor Ji-young Lee, the principal investigator of the study and a professor in the Department of Neurology at Seoul National University College of Medicine, who also practices at Boramae Hospital in Seoul (operated by Seoul National University Hospital), stated, “In this clinical trial, GV1001 (0.56 mg) demonstrated clinically meaningful benefits even with short-term treatment. Moving forward, we will conduct a thorough analysis of all available data to ensure that this research leads to a treatment that genuinely benefits patients.”

Building on its multi-mechanism approach, GemVax is advancing the development of GV1001 as a PSP treatment following its Alzheimer’s disease program. The company is actively preparing for a global Phase 3 clinical trial for PSP.

A GemVax representative stated, “Following our presentation at Neuro2024, our findings have once again drawn significant attention and positive feedback from leading global experts at this conference. With strong interest from both academia and the industry, we will continue to share our PSP research progress at international conferences.”

Meanwhile, GemVax is currently conducting a global Phase 2 trial for Alzheimer’s disease across seven countries in the U.S. and Europe. The company expects to complete patient dosing in the first half of next year and subsequently confirm the results.

[Attachment:  GemVax & KAEL Logo]

댓글목록

등록된 댓글이 없습니다.